BioVaxys Technology (BioVaxys Technology) Interest Expense : $0.00 Mil (TTM As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioVaxys Technology's interest expense for the three months ended in Jul. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioVaxys Technology's Operating Income for the three months ended in Jul. 2023 was $ -0.43 Mil. BioVaxys Technology's Interest Expense for the three months ended in Jul. 2023 was $ 0.00 Mil. BioVaxys Technology has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BioVaxys Technology Interest Expense Historical Data

The historical data trend for BioVaxys Technology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Interest Expense Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Interest Expense

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

BioVaxys Technology (OTCPK:BVAXF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioVaxys Technology's Interest Expense for the three months ended in Jul. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Jul. 2023 was $-0.43 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jul. 2023 was $0.00 Mil.

BioVaxys Technology's Interest Coverage for the quarter that ended in Jul. 2023 is calculated as

BioVaxys Technology had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. BioVaxys Technology Corp has enough cash to cover all of its debt. Its financial situation is stable.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.